Document Detail

EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
MedLine Citation:
PMID:  19018685     Owner:  NLM     Status:  MEDLINE    
Acute heart failure syndromes are a common cause of emergency department visits and hospitalization in North America and Europe. Although in-hospital mortality is relatively low, the postdischarge mortality and rehospitalization rates can be as high as 10-15 and 30%, respectively, within 60-90 days following discharge. It appears that the main reason for admission and readmission for heart failure is related to congestion manifested by dyspnea, jugular venous distension and edema. Often, congestion is associated with dilutional hyponatremia that is difficult to treat. Hyponatremia is an important predictor of increased mortality and the available therapies to treat congestion and/or hyponatremia are often ineffective and/or unsafe. Accordingly, there is an unmet need to develop a new agent that effectively relieves congestion due to high filling pressure without worsening renal function and improving or normalizing serum sodium in hyponatremic patients. This paper provides an overview of a new compound, tolvaptan, an oral selective V(2)-vasopressin antagonist in light of the recently published Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. The biochemical and pharmacological properties are discussed in conjunction with its clinical efficacy and safety, exploring the potential role of tolvaptan in the management of acute heart failure syndromes presenting with or without hyponatremia.
João L Cavalcante; Sadiya Khan; Mihai Gheorghiade
Related Documents :
3347445 - The benefit of cesarean section in acute myocardial infarction complicated by premature...
3788775 - Beneficial effect of taurine in rabbits with chronic congestive heart failure.
25100715 - Minimally invasive direct coronary bypass grafting versus percutaneous coronary interve...
19317305 - Fulminant hepatic necrosis resulting from heart failure.
2463575 - Late ventricular potentials and spontaneous and induced ventricular arrhythmias in dila...
20655115 - Therapeutic effects of resveratrol during acute periods following experimental ischemic...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  6     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-21     Completed Date:  2009-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1331-8     Citation Subset:  IM    
Henry Ford Heart and Vascular Institute, 2799 W Grand Blvd - K14, Detroit, MI 48202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Benzazepines / adverse effects,  pharmacology,  therapeutic use*
Cardiovascular Agents / adverse effects,  pharmacology,  therapeutic use*
Europe / epidemiology
Heart Failure / complications,  drug therapy*,  physiopathology
Hyponatremia / complications,  drug therapy
Middle Aged
North America / epidemiology
Randomized Controlled Trials as Topic
Receptors, Vasopressin / antagonists & inhibitors
Reg. No./Substance:
0/Benzazepines; 0/Cardiovascular Agents; 0/Receptors, Vasopressin; 150683-30-0/tolvaptan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fenofibrate: treatment of hyperlipidemia and beyond.
Next Document:  Evolution in cardiovascular care: highlights and observations from the ESC Congress 2008.